BR112023021867A2 - Composições de anticorpo anti-tslp e seus usos - Google Patents

Composições de anticorpo anti-tslp e seus usos

Info

Publication number
BR112023021867A2
BR112023021867A2 BR112023021867A BR112023021867A BR112023021867A2 BR 112023021867 A2 BR112023021867 A2 BR 112023021867A2 BR 112023021867 A BR112023021867 A BR 112023021867A BR 112023021867 A BR112023021867 A BR 112023021867A BR 112023021867 A2 BR112023021867 A2 BR 112023021867A2
Authority
BR
Brazil
Prior art keywords
tslp antibody
antibody compositions
compositions
tslp
antibody
Prior art date
Application number
BR112023021867A
Other languages
English (en)
Inventor
Alla Polozova
Dong Xiang
Hao Zhang
Kelly Fitzpatrick
Kristin Abrams
Marisa Joubert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112023021867A2 publication Critical patent/BR112023021867A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

composições de anticorpo anti-tslp e seus usos. o presente pedido se relaciona, de forma geral, com composições compreendendo o anticorpo anti-tslp tezepelumabe e seus derivados tendo atributos de qualidade do anticorpo.
BR112023021867A 2021-04-23 2022-04-22 Composições de anticorpo anti-tslp e seus usos BR112023021867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112023021867A2 true BR112023021867A2 (pt) 2023-12-19

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021867A BR112023021867A2 (pt) 2021-04-23 2022-04-22 Composições de anticorpo anti-tslp e seus usos

Country Status (18)

Country Link
US (1) US20240190951A1 (pt)
EP (1) EP4326766A1 (pt)
JP (1) JP2024517418A (pt)
KR (1) KR20240000537A (pt)
CN (1) CN117203233A (pt)
AR (1) AR125408A1 (pt)
AU (1) AU2022262421A1 (pt)
BR (1) BR112023021867A2 (pt)
CA (1) CA3216655A1 (pt)
CL (1) CL2023003155A1 (pt)
CO (1) CO2023014181A2 (pt)
CR (1) CR20230531A (pt)
IL (1) IL307540A (pt)
MX (1) MX2023012363A (pt)
PE (1) PE20240068A1 (pt)
TW (1) TW202308690A (pt)
UY (1) UY39736A (pt)
WO (1) WO2022226339A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
KR102519540B1 (ko) 2014-01-29 2023-04-10 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
RU2017134274A (ru) * 2015-03-11 2019-04-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Связывающие tslp белки
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
KR102560646B1 (ko) * 2017-08-01 2023-07-27 암젠 인크 질량 분광분석법으로의 분석을 위한 폴리펩티드 샘플의 실시간 제조를 위한 시스템 및 방법
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
EP3765856B1 (en) 2018-03-13 2023-09-27 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
MX2021002791A (es) 2018-10-15 2021-05-12 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
CA3137597A1 (en) 2019-04-30 2020-11-05 Amgen Inc. Data-driven predictive modeling for cell line selection in biopharmaceutical production
US20220260584A1 (en) 2019-06-05 2022-08-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins

Also Published As

Publication number Publication date
CO2023014181A2 (es) 2023-10-30
AU2022262421A1 (en) 2023-10-19
CR20230531A (es) 2024-01-08
CN117203233A (zh) 2023-12-08
WO2022226339A1 (en) 2022-10-27
PE20240068A1 (es) 2024-01-11
UY39736A (es) 2022-10-31
JP2024517418A (ja) 2024-04-22
CA3216655A1 (en) 2022-10-27
KR20240000537A (ko) 2024-01-02
CL2023003155A1 (es) 2024-04-19
MX2023012363A (es) 2023-11-01
US20240190951A1 (en) 2024-06-13
EP4326766A1 (en) 2024-02-28
IL307540A (en) 2023-12-01
WO2022226339A9 (en) 2023-08-24
AR125408A1 (es) 2023-07-12
TW202308690A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
BR112023021867A2 (pt) Composições de anticorpo anti-tslp e seus usos
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
BR112023022041A2 (pt) Anticorpos anti-tslp modificados
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
BR112023008490A2 (pt) Variantes de anticorpo bovino
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2021015846A (es) Derivados de antraciclina.
BR112022024382A2 (pt) Formas sólidas de pralsetinibe
BR112023024837A2 (pt) Anticorpos anti-ccr8
CL2024000305A1 (es) Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería
WO2019107831A3 (ko) 패오니플로린 또는 알비플로린을 포함하는, 내인성 노화 예방 또는 개선용 조성물
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
CL2020001851A1 (es) Moduladores de la expresión dnm2
BR112022003046A8 (pt) Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
PL433288A1 (pl) Sposób pozyskiwania sadzonek jesionu wyniosłego (Fraxinus excelsior L.) oraz pożywki nadające się do stosowania w tym sposobie
RS52118B (en) PROCEDURE FOR OBTAINING PROTOZOAL CULTURES AND THEIR APPLICATIONS
BRPI0601176A (pt) composições cosméticas ou dermatológicas, uso da composição, uso de pelo menos um éter com duas cadeias graxas e de pelo menos um álcool graxo e processo de tratamento cosmético
PL422316A1 (pl) Sposób otrzymywania przeciwciała monoklonalnego, przeciwciało monoklonalne, komórka CHO DG44, która koekspresjonuje przeciwciało monoklonalne oraz kompozycja je zawierająca
PL424209A1 (pl) 6-(tert-butylo)-3-dodecylo-3,4-dihydro-2H-benzo[e][1,3]oxazyna i sposób otrzymywania 6-(tert-butylo)-3-dodecylo-3,4-dihydro-2H-benzo[e][1,3]oxazyny